US FDA Generic Drug Approvals, Other Actions Declined As Approval Times Climbed In FY 2024

An increase in complex product submissions may explain median and mean approval time increases for ANDAs, but fewer actions across many categories could be a concern.

Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medication.
The FY 2024 generic drugs activity data likely will inform user fee reauthorization negotiations, which will begin in 2025. • Source: Alamy

More from Regulation

More from Generics Bulletin

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence

 
• By 

With sales remaining sluggish, on the back of fewer launches, Glenmark’s management nevertheless struck an upbeat tone when discussing the firm’s prospects in the US moving into the company’s 2026 financial year.

More Stelara Rivals Hit US, With Discounts Already Reaching 90%

 
• By 

As more Stelara biosimilars pile into the US market – including launches from Alvotech/Teva, Samsung Bioepis/Sandoz and Biocon Biologics – the latest data suggests that price competition for ustekinumab rivals could be fierce, with all three companies confirming to Generics Bulletin details of significant discounts to the brand.

GGB Awards Return To Frankfurt In 2025

 
• By 

The Global Generics & Biosimilars Awards is taking place in Frankfurt this October, with the event returning to Germany in its twelfth year for an even bigger and better awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.